Shares of India's Aurobindo Pharma rise 2.4% as Lyfius Pharma restarts Kakinada production, despite a 15% YTD drop.

• Restarting Kakinada facility boosts shares; analysts rate stock 'buy' with 1370 rupees median target.
• Stock up 2.4% on production resumption despite year, to, date decline of about 15%.
• LSEG data shows a positive outlook for Aurobindo Pharma amid operational recovery.